A subgroup analysis of the MiroCIP study to evaluate chemotherapy-induced peripheral neuropathy: symptom profile, severity, and analgesia efficacy depending on type of chemotherapy.

Abstract

Background: The multicenter, prospective MiroCIP observational study investigated the incidence, risk factors, and outcomes of chemotherapy-induced peripheral neuropathy (CIPN) by oxaliplatin- and taxane-based chemotherapies but did not examine their differences in detail. This post hoc subanalysis explored the differences between oxaliplatin- and taxane-based chemotherapy, in terms of CIPN symptom profile, severity, and response to analgesics.

Research design and methods: Patients with colorectal, gastric, non-small cell lung, or breast cancer, scheduled to receive oxaliplatin- or taxane-based chemotherapy, were followed for 12 months to assess the severity of sensory CIPN, by the Common Terminology Criteria for Adverse Events, and associated subjective and objective symptoms.

Results: Overall, 91 patients received oxaliplatin and 131 received a taxane. At 12 months, CIPN prevalence was 74.6% with oxaliplatin and 55.2% with a taxane. Grade ≥ 2 CIPN peaked at 9 months with oxaliplatin and at 3 months with a taxane, with most symptom scores following a similar trajectory. Analgesic efficacy differed between subgroups, providing marked reductions in pain/tingling scores in the taxane group but minimal effect in the oxaliplatin group.

Conclusions: CIPN course and symptoms vary with oxaliplatin- or taxane-based chemotherapy. Effective management should be tailored to the type of chemotherapy: oxaliplatin-treated patients may benefit from continuous monitoring of CIPN symptoms, whereas it may be beneficial for taxane-treated patients to receive appropriate analgesics at CIPN onset.

Trial registration: Japan Registry of Clinical Trials jRCTs031210101.